Analysis of regenerative medicine products market


Cite item

Full Text

Abstract

In recent years, based on review of normative documentation of Russian Federation, United States of America, Europe and Asian countries, financial reports and press releases of commercial and non-commercial organizations acting in the field of biological technologies and regenerative medicine, clinical trials databases, information resources of state institutions regulating medicinal drugs and regenerative medicine products circulation, significant growth of regenerative medicine products at advanced clinical stages is brought out, as well as significant growth of cumulative investments for regenerative medicine industry and growth of investments for this line of business on the part of major pharmaceutical and biotechnological companies. Analysis of regenerative medicine industry was performed, main factors for its course of development were recognized, and recommendations were provided on development of new Russian regenerative medicine markets

Full Text

Restricted Access

About the authors

I. N Korsakov

Central Clinical Hospital with Outpatient Health Center; Central State Medical Academy

Moscow, Russia

I. I Nadelyaeva

Central Clinical Hospital with Outpatient Health Center; Central State Medical Academy

Moscow, Russia

I. I Eremin

Central Clinical Hospital with Outpatient Health Center; Central State Medical Academy

Moscow, Russia

A. A Pulin

Central Clinical Hospital with Outpatient Health Center; Central State Medical Academy

Moscow, Russia

K. V Kotenko

Central State Medical Academy

Moscow, Russia

V. L Zorin

Central Clinical Hospital with Outpatient Health Center; Human Stem Cells Institute

Moscow, Russia

References

  1. Мау В., Улюкаев А. Глобальный кризис и тенденции экономического развития. Вопросыэкономики. 2014; 11: 4-24.
  2. Yongsiang L., editor. Science & Technology in China: A Roadmap to 2050 - Strategic General Report of the Chinese Academy of Sciences. Science Press Beijing, Springer-Verlag Berlin Heidelberg; 2010.
  3. European commission. Horizon 2020, http://ec.europa.eu/ programmes/horizon2020/en.
  4. Прогноз научно-технологического развития Российской Федерации на период до 2030 года (утв. Правительством РФ 3 января 2014 г.). Москва: Министерство образования и науки Российской Федерации. 2013.
  5. Mason C., Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008; 3(1): 1-5.
  6. The Economist. Prometheus unbound: Researchers have yet to realize the old dream of regenerating organs. But they are getting closer, http://www.economist.com/news/science-and-technology/21580440-researchers-have-yet-realise-old-dream-regenerating-organs-they-are
  7. Alliance for Regenerative Medicine. Q1 Alliance for regenerative medicine 2016 Quarterly data report on gene and cellular therapy and the regenerative medicine sector. ARM; 2016.
  8. Dove E.S., Ozdemir V. What Role for Law, Human Rights, and Bioethics in an Age of Big Data, Consortia Science, and Consortia Ethics? The Importance of Trustworthiness.Laws. 2015; 4(3): 515540.
  9. Burke W., Appelbaum P., Dame L. The translational potential of research on the ethical, legal, and social implications of genomics. Genet Med. 2015; 17(1): 12-20.
  10. Yoshizawa G., Ho C.W., Zhu W. ELSI practices in genomic research in East Asia: implications for research collaboration and public participation. Genome Med. 2014; 6(5): 39.
  11. Alliance for Regenerative Medicine. Alliance for regenerative medicine 2015 Annual data report on gene and cellular therapy and the regenerative medicine sector.ARM; 2016, https://alliancerm.org/ page/arm-presentations-publications.
  12. Alliance for Regenerative Medicine. Alliance for regenerative medicine 2016 Annual data report on gene and cellular therapy and the regenerative medicine sector.ARM; 2017, https://alliancerm.org/ page/arm-presentations-publications.
  13. Alliance for Regenerative Medicine. Alliance for regenerative medicine 2014 Annual data report on gene and cellular therapy and the regenerative medicine sector.ARM; 2015, https://alliancerm.org/ page/arm-presentations-publications.
  14. Alliance for Regenerative Medicine. Regenerative medicine annual report: March 2012-March 2013. ARM; 2013, https:// alliancerm.org/page/arm-presentations-publications.
  15. Ernest & Young Global Limited. Biotechnology industry report 2013: Beyond borders. Matters of evidence.Ernest & Young Global Limited; 2013.
  16. Axis Research Mind. Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019. Report Detail, http://www. reportsnreports.com/reports/379103-regenerative-medicine-global-trends-estimates-and-forecasts-2013-2019.html
  17. Future Market Insights. Regenerative Medicine Market: Tissue Engineering Technology will Remain Key to Overall Growth: Global Industry Analysis and Opportunity Assessment, 2015-2019. Preview Analysis, http://www.futuremarketinsights.com/reports/ regenerative-medicine-market
  18. American Diabetes Association. Statistics About Diabetes: Overall Numbers, Diabetes and Prediabetes, http://www.diabetes.org/ diabetes-basics/statistics/.
  19. Fibrocell Inc. SEC Filings Fibrocell Inc., http://ir.fibrocell.com/ phoenix.zhtml?c=253777&p=irol-sec.
  20. ПАО «Институт стволовых клеток человека». Публичные годовые отчеты, http://hsci.ru/investoram-i-aktsioneram/informatsiia-dlia-investorov/publichnye_godovye_otchety.
  21. QYResearch Group. Global Regenerative Medicine Industry 2016 Market Research Report.Report Description, http://www. reportsnreports.com/reports/580611-global-regenerative-medicine-industry-2016-market-research-report.html.
  22. MarketsandMarkets. Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), Product (Cell-Based, Acellular), Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology) -Forecast to 2021. Report Description, http://www.reportsnreports. com/reports/858290-regenerative-medicine-market-by-therapy-cell-therapy-tissue-engineering-immunotherapy-gene-therapy-product-cell-based-acellular-applications-orthopedic-musculoskeletal-disorders-dermatology-oncology-st-to-2021.html.
  23. Research Nester. Global Stem cells & Regenerative Medicine Market Overview. Preview Analysis, http://www.researchnester. com/reports/stem-cell-regenerative-medicine-market-global-demand-analysis-opportunity-outlook-2021/156.
  24. Food and Drug Administration. A list of marketed products from the Office of Cellular, Tissue and Gene Therapies, http://www. fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/default.htm.
  25. Bipartisan Policy Center. Bipartisan REGROW Act Would Advance Regenerative Cell Therapy, http://bipartisanpolicy.org/press-release/ bipartisan-regrow-act-would-advance-regenerative-cell-therapy/.
  26. Turner L.P., Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. CellStemCell. 2016; 19(2): 154-7.
  27. Mizuho Bank. Life Sciences and Biotechnology Industry Clusters in Europe - Building Bridges between Science and Industry. Mizuho Industry Focus. Vol. 122.The Bank; 2013.
  28. European Commission. Regulation (EC) No 1394/2007 of The European Parliament and of The Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004
  29. Paul-Ehrlich-Institut. PEI table of ATMP (Advanced therapy medical products) with a valid marketing authorization, http://www. pei.de/EN/medicinal-products/advanced-therapy-medicinal-productsatmp/advanced-therapy-medicinal-products-atmp-node.html.
  30. Beretta R. Is there health inequity in Europe today? The “Strange case” of the application of anEuropian regulation to cartilage repair. Journal of health and social sciences. 1(1): 37-46.
  31. Regenerative medical products distributed on the world market, http://www.skip.med.keio.ac.jp/frontline/worldprod.
  32. McCormack K. CIRM's Randy Mills: New FDA rules for stem cells won't fix the problem, https://blog.cirm.ca.gov/2016/09/14/ cirms-randy-mills-new-fda-rules-for-stem-cells-wont-fix-the-problem/.
  33. Technavio. Regenerative Medicine Market in Japan 2016-2020, http://www.reportsnreports.com/reports/709602-regenerative-medicine-market-in-japan-2016-2020.html.
  34. Remuzat C., Toumi M., Jorgensen J., Kefalas P. Market access pathways for cell therapies in France. J. Mark. Access Health Policy. 2015; doi: 10.3402/jmahp.v3.29094.
  35. Pfizer Inc. 2015 Financial Report. Pfizer Inc.; 2016.
  36. Sanofi. Half-year financial report 2016 Edition.Sanofi; 2016.
  37. Jorgensen J., Kefalas P. Reimbursement of licensed cell and gene therapies across the major European healthcare markets. J Mark Access Health Policy. 2015; doi: 10.3402/jmahp.v3.29321

Copyright (c) 2017 PJSC Human Stem Cells Institute


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 57156 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies